RIO DE JANEIRO, BRAZIL - U.S. biotech Moderna announced Tuesday that its Covid-19 vaccine produced neutralizing activity against variants of the coronavirus, including Delta, in a not-yet-peer-reviewed laboratory study.
According to a statement, the vaccine produced antibody titers against all variants tested in vitro, including Beta, identified in South Africa; Delta, identified in India; and others identified in Nigeria, Uganda, and Angola.
Moderna, which is working on a clinical development strategy to protect against variants, used serum samples from eight participants obtained one week after the second dose in the first phase of the clinical trial . . .